To evaluate whether this selective activation also led to improved tumor-killing capacity, we cocultured αROR1 CAR-T cells expressing either surface HER2 (HER2t) or a control CD19 transduction marker (CD19t, negative control) with NCI-H1975 tumor cells, in the presence or absence of cis-targeted split Neo-2/15 proteins. The gene discussed is ERBB2; the disease is neoplasm.